Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL -1.53%64 PB Ratio is 0.51 as of Jul. 15, 2026, which is 88% below its 10-year median of 4.34. GuruFocus rates ZJYL with a GF Score™ of 64/100 and a GF Value™ of $14.58 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Jin Medical International ranks better than 92.76% on this metric.
Jin Medical International Ltd stock PB Ratio (=0.52) is close to 5-year low of 0.49.
The historical rank and industry rank for Jin Medical International's PB Ratio or its related term are showing as below:
ZJYL'
s PB Ratio Range Over the Past 10 Years
Min: 0.49 Med: 4.34 Max: 85.21
Current: 0.51
During the past 6 years, Jin Medical International's highest PB Ratio was 85.21. The lowest was 0.49. And the median was 4.34.
ZJYL's PB Ratio is ranked better than 92.76% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs ZJYL: 0.51
During the past 12 months, Jin Medical International's average Book Value Per Share Growth Rate was 2.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 24.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 24.20% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Jin Medical International was 30.20% per year. The lowest was 24.40% per year. And the median was 26.70% per year.
Back to Basics: PB Ratio
Jin Medical International (NAS:ZJYL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jin Medical International PB Ratio Related Terms
Jin Medical International PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Jin Medical International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jin Medical International's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jin Medical International (ZJYL) has a PB Ratio of 0.51 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jin Medical International and its competitors. This is 88% below median its historical median of 4.34. Over the past decade, Jin Medical International's PB Ratio has ranged from 0.49 to 85.21. According to the industry distribution chart, Jin Medical International ranks #57 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 7.2%.
Is Jin Medical International's PB Ratio too high?
Jin Medical International's current PB Ratio of 0.51 is 88% below median its 10-year median of 4.34. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 85.21. The Medical Devices & Instruments industry median PB Ratio is 2.05. Jin Medical International's value of 0.51 is 75.1% below this industry median. Based on the distribution chart, Jin Medical International ranks #57 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Jin Medical International has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's PB Ratio compare to RVP and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #57 out of 787 companies for PB Ratio. This places Jin Medical International in the top 7% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Jin Medical International's value of 0.51 is 75.1% below this benchmark. Historically, Jin Medical International's own PB Ratio has ranged from 0.49 to 85.21 over the past decade. While the company's 10-year median is 4.34 vs. the industry median of 2.05, Jin Medical International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current PB Ratio of 0.51 is 75.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current PB Ratio is 0.51, which is 88% below median its own 10-year median of 4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.58, compared to a current price of $1.93 — trading 86.8% below its estimated fair value. The current PB Ratio is 0.51, which is 88% below median its 10-year median of 4.34 and 75.1% below the Medical Devices & Instruments industry median of 2.05. Jin Medical International's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current PB Ratio is 0.51 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $1.93 is trading 86.8% below its estimated GF Value™ of $14.58.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
PB Ratio: 0.51 (88% below median its 10-year median of 4.34)
GF Value™: $14.58 vs. price of $1.93 (86.8% below fair value)
Industry Position: 75.1% below the Medical Devices & Instruments median (#57 of 787)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
64GF Score
Get the complete analysis for ZJYL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
